<DOC>
	<DOCNO>NCT01946568</DOCNO>
	<brief_summary>A phase one study characterize pharmacokinetics dalbavancin pediatric patient age 3 month 11 year ( inclusive ) follow intravenous administration single dose dalbavancin .</brief_summary>
	<brief_title>A Single Dose Study To Investigate The Pharmacokinetics Safety Of Dalbavancin In Hospitalized Children Aged 3 Months 11 Years .</brief_title>
	<detailed_description>This open label , multi center study investigate pharmacokinetics , safety tolerability single dose intravenous dalbavancin hospitalize pediatric patient know suspected bacterial infection . Patients enrol result evaluate 3 age cohort follow : Cohort 1 : Patients 6 year 11 year age , inclusive ; Cohort 2 : Patients 2 year &lt; 6 year age ; Cohort 3 : Patients 3 month &lt; 2 year age . All patient cohort administer single dose dalbavancin addition background anti infective treatment chosen investigator accord standard care . Pharmacokinetic sample obtain various timepoints . Dalbavancin administer time ( , ) standard care therapy .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Dalbavancin</mesh_term>
	<mesh_term>Teicoplanin</mesh_term>
	<criteria>Hospitalized patient receive least 24 hour appropriate noninvestigational intravenous antiinfective treatment know suspected bacterial infection exception urinary tract infection . Written parental inform consent . Able comply protocol duration study . Expected survive throughout study . Normal audiologic assessment within 3 day prior study drug infusion . Investigational drug within 30 day 5 halflives , whichever long , precede first dose study medication . History fluctuant hearing , persistent tinnitus , balance disorder , otologic surgery disease , tumor head , neck , auditory system , head injury , Meniere 's disease , autoimmune inner ear disease , perilymphatic fistula , CNS disorder result hear deficit , significant noise exposure . Significant exposure aminoglycoside antibiotic chemotherapy currently within week prior enrollment study current use loop diuretic . Patients continue vancomycin treatment anticipate begin vancomycin glycopeptide treatment 7 day period dalbavancin administration . Patients clinically significant abnormality associate underlying disease . Aminotransferases ( AST , ALT ) &gt; 5 x ULN ; total bilirubin alkaline phosphatase ) &gt; 2 x ULN . Albumin &lt; half low limit normal physical exam evidence malnutrition . Patients less one year age , bear gestational age le 32 week . Positive urine ( serum ) pregnancy test screening ( post menarchal female ) admission ( prior dosing ) . Known hypersensitivity glycopeptides . Calculated creatinine clearance &lt; 30 ml/min use Schwartz method . Pregnant nursing female . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation investigational product administration may interfere interpretation study result , judgment investigator , would make patient inappropriate entry study .</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>